Literature DB >> 28160460

The Timing of Immunomodulation Induced by Mesenchymal Stromal Cells Determines the Outcome of the Graft in Experimental Renal Allotransplantation.

Ana Merino, Elia Ripoll, Laura de Ramon, Nuria Bolaños, Montserrat Goma, Oriol Bestard, Nuria Lloberas, Josep M Grinyo, Juan Torras Ambròs.   

Abstract

The immunomodulatory characteristics of mesenchymal stromal cells (MSCs) may lead to multifaceted strategies in rejection of organ transplantation. This study was designed to investigate, first, the effect of the donor-type MSCs from Wistar rats on the immune system of immunocompetent Lewis rats and, second, the rejection responses in a renal transplantation model of Wistar to Lewis. In the first experimental model, MSCs from the bone marrow induced a systemic immune response in the immunocompetent Lewis rats, characterized by two different phases. In the initial phase (days 1-3 after MSCs infusion), the main findings were a decrease in the percentage of the main peripheral blood (PB) lymphocyte subpopulations [T cells, B cells, and natural killer (NK) cells], an increase in the FOXP3 MFI in Tregs, and an elevated concentration of circulating proinflammatory cytokines (IL-1β and TNF-α). In the late phase (days 4-6), the percentage of T cells, B cells, and NK cells returned to baseline levels; the concentration of circulating IL-1β and TNF-α decreased; and the level of anti-inflammatory cytokines (IL-10 and IL-4) increased with respect to the initial phase. In the allogeneic kidney transplantation model, rats were randomized into four groups: nontreated, cyclosporine oral administration, and two groups of rats treated with two different schedules of MSC infusion: 4 days (MSCs-4) and 7 days (MSCs-7) before kidney transplantation and in both a further infusion at the day of transplantation. Both MSC treatments decreased the percentage of T, B, and NK cells in PB. Creatinine levels, survival, and histological parameters were better in MSCs-7 than in MSCs-4. We can conclude that MSCs, by themselves, produce changes in the immune system; they do not need a pathological condition to produce immunomodulatory responses. In the renal allograft model, the optimal time schedule for MSC infusion before grafting was 7 days to prevent acute rejection.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28160460      PMCID: PMC5657755          DOI: 10.3727/096368917X695010

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  28 in total

Review 1.  Immunosuppressive properties of mesenchymal stem cells: advances and applications.

Authors:  M P De Miguel; S Fuentes-Julián; A Blázquez-Martínez; C Y Pascual; M A Aller; J Arias; F Arnalich-Montiel
Journal:  Curr Mol Med       Date:  2012-06       Impact factor: 2.222

2.  Isogeneic MSC application in a rat model of acute renal allograft rejection modulates immune response but does not prolong allograft survival.

Authors:  M Koch; A Lehnhardt; X Hu; B Brunswig-Spickenheier; M Stolk; V Bröcker; M Noriega; M Seifert; C Lange
Journal:  Transpl Immunol       Date:  2013-08-28       Impact factor: 1.708

3.  Immunological aspects of allogeneic and autologous mesenchymal stem cell therapies.

Authors:  M J Hoogduijn; M Roemeling-van Rhijn; S S Korevaar; A U Engela; W Weimar; C C Baan
Journal:  Hum Gene Ther       Date:  2011-08-10       Impact factor: 5.695

4.  Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM.

Authors:  I Müller; S Kordowich; C Holzwarth; C Spano; G Isensee; A Staiber; S Viebahn; F Gieseke; H Langer; M P Gawaz; E M Horwitz; P Conte; R Handgretinger; M Dominici
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

5.  Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery.

Authors:  Massimo Giuliani; Noufissa Oudrhiri; Zaeem M Noman; Amelia Vernochet; Salem Chouaib; Bruno Azzarone; Antoine Durrbach; Annelise Bennaceur-Griscelli
Journal:  Blood       Date:  2011-07-29       Impact factor: 22.113

6.  Mesenchymal stem cells induce functionally active T-regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis.

Authors:  Roberta Tasso; Cristina Ilengo; Rodolfo Quarto; Ranieri Cancedda; Rachel R Caspi; Giuseppina Pennesi
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-16       Impact factor: 4.799

7.  Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus.

Authors:  X Li; D Wang; J Liang; H Zhang; L Sun
Journal:  Bone Marrow Transplant       Date:  2012-10-15       Impact factor: 5.483

Review 8.  Mesenchymal stem cell-based therapy.

Authors:  Vaibhav Mundra; Ivan C Gerling; Ram I Mahato
Journal:  Mol Pharm       Date:  2012-12-24       Impact factor: 4.939

9.  Mesenchymal stem cells induce an inflammatory response after intravenous infusion.

Authors:  Martin J Hoogduijn; Marieke Roemeling-van Rhijn; Anja U Engela; Sander S Korevaar; Fane K F Mensah; Marcella Franquesa; Ron W F de Bruin; Michiel G H Betjes; Willem Weimar; Carla C Baan
Journal:  Stem Cells Dev       Date:  2013-08-09       Impact factor: 3.272

10.  A comparison of the reparative and angiogenic properties of mesenchymal stem cells derived from the bone marrow of BALB/c and C57/BL6 mice in a model of limb ischemia.

Authors:  Flavia Franco Cunha; Leonardo Martins; Priscila Keiko Matsumoto Martin; Roberta Sessa Stilhano; Sang Won Han
Journal:  Stem Cell Res Ther       Date:  2013-07-26       Impact factor: 6.832

View more
  8 in total

1.  Administration of mesenchymal stromal cells before renal ischemia/reperfusion attenuates kidney injury and may modulate renal lipid metabolism in rats.

Authors:  Pauline Erpicum; Pascal Rowart; Laurence Poma; Jean-Marie Krzesinski; Olivier Detry; François Jouret
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

2.  Membrane particles generated from mesenchymal stromal cells modulate immune responses by selective targeting of pro-inflammatory monocytes.

Authors:  Fabiany da C Gonçalves; Franka Luk; Sander S Korevaar; Rachid Bouzid; Ana H Paz; Carmen López-Iglesias; Carla C Baan; Ana Merino; Martin J Hoogduijn
Journal:  Sci Rep       Date:  2017-09-21       Impact factor: 4.379

3.  Biodistribution and Immunogenicity of Allogeneic Mesenchymal Stem Cells in a Rat Model of Intraarticular Chondrocyte Xenotransplantation.

Authors:  Maribel Marquina; Javier A Collado; Magdiel Pérez-Cruz; Pablo Fernández-Pernas; Juan Fafián-Labora; Francisco J Blanco; Rafael Máñez; María C Arufe; Cristina Costa
Journal:  Front Immunol       Date:  2017-11-06       Impact factor: 7.561

Review 4.  Preconditioning is an effective strategy for improving the efficiency of mesenchymal stem cells in kidney transplantation.

Authors:  Lingfei Zhao; Chenxia Hu; Fei Han; Fanghao Cai; Junni Wang; Jianghua Chen
Journal:  Stem Cell Res Ther       Date:  2020-05-24       Impact factor: 6.832

Review 5.  Adipose-Derived Stem/Stromal Cells in Kidney Transplantation: Status Quo and Future Perspectives.

Authors:  Gabriele Storti; Evaldo Favi; Francesca Albanesi; Bong-Sung Kim; Valerio Cervelli
Journal:  Int J Mol Sci       Date:  2021-10-17       Impact factor: 5.923

Review 6.  Ex Vivo Mesenchymal Stem Cell Therapy to Regenerate Machine Perfused Organs.

Authors:  Christina Bogensperger; Julia Hofmann; Franka Messner; Thomas Resch; Andras Meszaros; Benno Cardini; Annemarie Weissenbacher; Rupert Oberhuber; Jakob Troppmair; Dietmar Öfner; Stefan Schneeberger; Theresa Hautz
Journal:  Int J Mol Sci       Date:  2021-05-15       Impact factor: 5.923

7.  The differentiation of mesenchymal stem cells to vascular cells regulated by the HMGB1/RAGE axis: its application in cell therapy for transplant arteriosclerosis.

Authors:  Xiaohu Meng; Min Chen; Wenjie Su; Xuan Tao; Mingyang Sun; Xiaoping Zou; Rongchao Ying; Wei Wei; Baolin Wang
Journal:  Stem Cell Res Ther       Date:  2018-04-03       Impact factor: 6.832

Review 8.  Cellular therapies in organ transplantation.

Authors:  Martin J Hoogduijn; Fadi Issa; Federica Casiraghi; Marlies E J Reinders
Journal:  Transpl Int       Date:  2021-01-15       Impact factor: 3.842

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.